China National Medical Products Administration approves Biktarvy (bictegravir, emtricitabine and tenofovir alafenamide) for treatment of HIV-1 infection

Gilead

9 August 2019 - Biktarvy demonstrated high efficacy and a high barrier to resistance in clinical trials through 48 weeks.

Gilead Sciences announced today that the China National Medical Products Administration (NMPA) has approved Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg), a once-daily single tablet regimen (STR) for the treatment of HIV-1 infection. 

Biktarvy combines the novel, unboosted integrase strand transfer inhibitor (INSTI) bictegravir with the demonstrated safety and efficacy profile of the Descovy (emtricitabine 200 mg/tenofovir alafenamide 25 mg; dual nucleoside reverse transcriptase inhibitor backbone and is the smallest INSTI-based triple-therapy STR available. 

In China, Biktarvy is indicated for the treatment of HIV-1 infection in adults without present or past evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir.

Read Gilead press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Medicine , HIV infection , China